Nasus Pharma Partners with Aptar to Accelerate NS002 Intranasal Epinephrine Development
核心洞察
Nasus Pharma has executed comprehensive agreements with Aptar (搜索), a leading global drug delivery systems manufacturer, to support NS002's clinical development and commercialization pathway.
The collaboration provides Nasus with access to Aptar (搜索)'s commercially proven Unit Dose System technology and established regulatory pathways for both FDA and EMA submissions.
NS002 is being developed as a needle-free intranasal powder epinephrine alternative to autoinjectors for anaphylaxis (搜索) patients, utilizing Nasus's proprietary powder-based intranasal technology.
Nasus Pharma Ltd. (NYSE: NSRX), a clinical-stage pharmaceutical company developing innovative intranasal products for emergency medical conditions, has announced comprehensive agreements with Aptar France S.A.S. (搜索) and AptarGroup, Inc. to advance its NS002 intranasal powder epinephrine program. The collaboration with the leading global drug delivery systems manufacturer establishes a framework to support NS002's development through regulatory submissions and commercialization.
Strategic Partnership Strengthens Development Infrastructure
The partnership provides Nasus Pharma with access to Aptar (搜索)'s commercially proven Unit Dose System technology and validated dosing infrastructure. "This collaboration represents a significant milestone for Nasus Pharma and for our NS002 program," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "Through this collaboration, Nasus Pharma will secure a commercially proven Unit Dose System technology, providing us with a validated dosing infrastructure."
The strategic relationship enables Nasus to leverage established regulatory pathways, manufacturing capabilities, and supply chain infrastructure. According to Teleman, this approach is "accelerating NS002's path to market while reducing development risks."
Regulatory and Commercial Framework
The collaboration establishes comprehensive support for NS002's development through regulatory submissions with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The partnership provides Nasus with access to Aptar (搜索)'s technical expertise and manufacturing capabilities to advance NS002 through current clinical development to commercialization in alignment with the company's timeline and objectives.
NS002 Product Profile
NS002 represents Nasus Pharma's intranasal powder epinephrine product candidate being developed as a needle-free alternative to epinephrine autoinjectors for patients with anaphylaxis (搜索). The product utilizes the company's proprietary powder-based intranasal (PBI) technology, designed for rapid and reliable drug delivery.
The PBI formulation leverages the nasal cavity's rich vascular network for quick absorption and uses uniform spherical powder particles for broad dispersion. According to the company, this approach potentially offers faster, higher absorption compared to liquid-based nasal products, making intranasal administration particularly suitable for situations requiring rapid drug delivery through needle-free, easy-to-use alternatives.